Literature DB >> 20734203

IgA nephropathy associated with a novel N-terminal mutation in factor H.

Roland Schmitt1, Rafael T Krmar, Anncharlotte Kristoffersson, Magnus Söderberg, Diana Karpman.   

Abstract

Most patients with IgA nephropathy exhibit complement deposition in the glomerular mesangium. Certain cases of IgA nephropathy have been associated with reduced levels of complement factor H. A recent study could not demonstrate mutations at the C-terminal of factor H. We describe a novel heterozygous mutation in factor H, position A48S (nucleotide position 142 G > T, alanine > serine), detected in exon 2 of a 14-year-old girl with IgA nephropathy. The patient exhibited reduced levels of C3 and factor H, the latter suggesting that the mutation affected factor H secretion. The patient developed initial signs and symptoms of glomerulonephritis at the age of 9 years but presented again at the age of 14 years with weight gain, renal failure, nephrotic-range proteinuria and malignant hypertension. Blood tests suggested the development of microangiopathic hemolytic anemia (MAHA) but the renal biopsy was mostly indicative of chronic changes associated with IgA nephropathy as well as vascular changes associated with malignant hypertension. Immunofluorescence exhibited deposits of IgA, C3, and IgM. Screening of the factor H gene revealed, in addition to the mutation, three heterozygous hemolytic uremic syndrome -associated risk polymorphisms (-257 c/t, 2089 a/g, and 2881 g/t) which may have increased the patient's susceptibility to the occurrence of MAHA triggered by malignant hypertension. The combined clinical picture of IgA nephropathy and MAHA may have been partly related to the alterations in factor H.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20734203     DOI: 10.1007/s00431-010-1279-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  27 in total

1.  Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP)

Authors:  H E Gerritsen; P L Turecek; H P Schwarz; B Lämmle; M Furlan
Journal:  Thromb Haemost       Date:  1999-11       Impact factor: 5.249

Review 2.  Liver-kidney transplantation to cure atypical hemolytic uremic syndrome.

Authors:  Jeffrey M Saland; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

3.  A clinicopathologic study of thrombotic microangiopathy in the setting of IgA nephropathy.

Authors:  A Chang; J Kowalewska; K D Smith; R F Nicosia; C E Alpers
Journal:  Clin Nephrol       Date:  2006-12       Impact factor: 0.975

4.  Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H.

Authors:  S Kühn; P F Zipfel
Journal:  Eur J Immunol       Date:  1996-10       Impact factor: 5.532

Review 5.  Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy.

Authors:  P Ruggenenti; G Remuzzi
Journal:  Am J Kidney Dis       Date:  1996-04       Impact factor: 8.860

6.  Activation of the alternative pathway of complement by human serum IgA.

Authors:  P S Hiemstra; A Gorter; M E Stuurman; L A Van Es; M R Daha
Journal:  Eur J Immunol       Date:  1987-03       Impact factor: 5.532

7.  Mesangial C4d deposition: a new prognostic factor in IgA nephropathy.

Authors:  Mario Espinosa; Rosa Ortega; Jose Manuel Gómez-Carrasco; Fernando López-Rubio; María López-Andreu; María Ovidia López-Oliva; Pedro Aljama
Journal:  Nephrol Dial Transplant       Date:  2008-10-08       Impact factor: 5.992

8.  Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome.

Authors:  F Vaziri-Sani; L Holmberg; A G Sjöholm; A-C Kristoffersson; M Manea; V Frémeaux-Bacchi; I Fehrman-Ekholm; R Raafat; D Karpman
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

9.  Is complement factor H a susceptibility factor for IgA nephropathy?

Authors:  Matthew Edey; Lisa Strain; Roy Ward; Saeed Ahmed; Trevor Thomas; Timothy H J Goodship
Journal:  Mol Immunol       Date:  2009-01-21       Impact factor: 4.407

10.  Deposition of C4-binding protein and beta 1H globulin in kidneys of patients with IgA nephropathy.

Authors:  Y Tomino; H Sakai; Y Nomoto; M Endoh; S Arimori; T Fujita
Journal:  Tokai J Exp Clin Med       Date:  1981-04
View more
  3 in total

1.  Eculizumab treatment for rescue of renal function in IgA nephropathy.

Authors:  Therese Rosenblad; Johan Rebetz; Martin Johansson; Zivile Békássy; Lisa Sartz; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2014-06-13       Impact factor: 3.714

2.  Factors influencing treatment of atypical hemolytic uremic syndrome.

Authors:  Carla M Nester; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-08-18       Impact factor: 10.614

3.  Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy.

Authors:  Precil Diego Miranda de Menezes Neves; Rafael A Souza; Fábio M Torres; Fábio A Reis; Rafaela B Pinheiro; Cristiane B Dias; Luis Yu; Viktoria Woronik; Luzia S Furukawa; Lívia B Cavalcante; Stanley de Almeida Araújo; David Campos Wanderley; Denise M Malheiros; Lectícia B Jorge
Journal:  PLoS One       Date:  2020-11-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.